MSD (Belgium)

Recent papers from MSD (Belgium)

1. Understanding motivations for agroforestry maintenance and adoption: a comparative analysis in EuropeAgricultural and Food Economics · 2026
2. Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.Journal of Clinical Oncology · 2026
3. Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countriesJournal of Pharmaceutical Policy and Practice · 2026
4. Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparisonJournal of Medical Economics · 2026
5. Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancerQuality of Life Research · 2026
6. The effect of prolonged glucose infusion on resting-state fMRI signal fluctuations at 7 TMagnetic Resonance Imaging · 2026
7. Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in CanadaJournal of Medical Economics · 2025
8. Are Narrative CVs contributing towards shifting research culture? Workshop Report from the 2023 Recognition and Rewards FestivalF1000Research · 2025
9. Reproducibility of the Determination of ¹³C‐Labeling of Glutamate and Glutamine in the Human Brain Using selPOCE‐MRS at 7 T Upon [U‐¹³C]–Labeled Glucose InfusionNMR in Biomedicine · 2025
10. A Global Industry Survey on Post-Approval Change Management and Use of RelianceTherapeutic Innovation & Regulatory Science · 2024
11. A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participantsInvestigational New Drugs · 2024
12. Quantifying public and private investment in European biopharmaceutical research and developmentHealth Affairs Scholar · 2024
13. A Global Industry Survey on Post-Approval Change Management and Use of Reliance2024
14. Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analysesBMC Medicine · 2024
15. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysisFuture Oncology · 2024
16. Pediatric Market Access: A Qualitative StudyTherapeutic Innovation & Regulatory Science · 2024
17. Polarisation, Violent Extremism and Resilience in Europe today: An analytical frameworkENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
18. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvementsFrontiers in Medicine · 2023
19. Dealing with censoring in a network meta-analysis of time-to-event dataResearch Methods in Medicine & Health Sciences · 2023
20. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s ChoiceEuropean Journal of Cancer · 2023